White blood cell count nadir to zero following intensive chemotherapy as a predictive factor for patients with acute myeloid leukemia

被引:0
|
作者
Fang, Jacob [1 ]
Bosma, Grace [2 ]
Aisner, Dara [3 ]
McMahon, Christine [2 ]
Amaya, Maria [2 ]
Schwartz, Marc [2 ]
Kaiser, Jeff [2 ]
Abbott, Diana [2 ]
Pan, Zenggang [3 ]
Schowinsky, Jeffrey [3 ]
Pang, Changlee [3 ]
Gutman, Jonathan A. [2 ]
Pollyea, Daniel A. [2 ]
机构
[1] Univ Colorado, Sch Med, Aurora, CO 80045 USA
[2] Univ Colorado, Div Med Hematol, Aurora, CO USA
[3] Univ Colorado, Div Pathol, Aurora, CO USA
关键词
Acute myeloid leukemia; predictive factors; WBC nadir; induction chemotherapy; stem cell transplant; overall survival; progression free survival; INDUCTION; ADULTS;
D O I
10.1080/10428194.2024.2323677
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Predictors for response to intensive therapy in AML have focused on baseline factors: percent leukemic blasts in marrow, cytogenetic/molecular genetic abnormalities, and presence of secondary AML. Non-baseline dynamic factors, occurring after induction but before response, may be useful for decisions related to salvage chemotherapy. We hypothesized white blood cell (WBC) count nadir after induction may be a real time indicator of treatment efficacy. We also examined whether time to stem cell transplant (SCT) or baseline molecular genetic abnormalities are associated with a low nadir. Data showed WBC nadir = 0 was a negative predictor for response to intensive induction and was correlated with reduced overall survival and progression free survival. Patients with WBC nadir = 0 did not have a significantly longer time to SCT, and none of the mutations increased the likelihood of reaching WBC nadir = 0. WBC nadir may be a useful real-time monitor in AML patients receiving intensive induction chemotherapy.
引用
收藏
页码:800 / 807
页数:8
相关论文
共 50 条
  • [41] Quality of life in adult patients with acute myeloid leukemia receiving intensive and prolonged chemotherapy – a longitudinal study
    A Schumacher
    T Kessler
    T Büchner
    D Wewers
    J van de Loo
    Leukemia, 1998, 12 : 586 - 592
  • [42] Economic burden in US patients with newly diagnosed acute myeloid leukemia receiving intensive induction chemotherapy
    Huggar, David
    Knoth, Russell L.
    Copher, Ronda
    Cao, Zhun
    Lipkin, Craig
    McBride, Ali
    LeBlanc, Thomas W.
    FUTURE ONCOLOGY, 2022, 18 (32) : 3609 - 3621
  • [43] Maintenance therapy with a combination of azacitidine, danazol, and thalidomide after intensive chemotherapy in patients with acute myeloid leukemia
    Zheng, Fang
    Li, Qianqian
    Yang, Sisi
    Zhou, Zhen
    Zeng, Qingfan
    Liu, Kaiqi
    HEMATOLOGY, 2023, 28 (01)
  • [44] Quality of life in adult patients with acute myeloid leukemia receiving intensive and prolonged chemotherapy -: a longitudinal study
    Schumacher, A
    Kessler, T
    Büchner, T
    Wewers, D
    van de Loo, J
    LEUKEMIA, 1998, 12 (04) : 586 - 592
  • [45] The occurrence of T-cell malignancies in patients treated by chemotherapy for acute myeloid leukemia
    P. Lemež
    K. Michalová
    Annals of Hematology, 1997, 74 : 203 - 203
  • [46] Health-related quality of life in acute myeloid leukemia patients not eligible for intensive chemotherapy: results of a systematic literature review
    Forsythe, Anna
    Kwon, Christina S.
    Bell, Timothy
    Smith, T. Alexander
    Arondekar, Bhakti
    CLINICOECONOMICS AND OUTCOMES RESEARCH, 2019, 11 : 87 - 98
  • [47] ELN 2017 classification significantly impacts the risk of early death in acute myeloid leukemia patients receiving intensive induction chemotherapy
    Naama Keren-Froim
    Gabriel Heering
    Gal Sharvit
    Maya Zlotnik
    Arnon Nagler
    Avichai Shimoni
    Abraham Avigdor
    Jonathan Canaani
    Annals of Hematology, 2022, 101 : 309 - 316
  • [48] ELN 2017 classification significantly impacts the risk of early death in acute myeloid leukemia patients receiving intensive induction chemotherapy
    Keren-Froim, Naama
    Heering, Gabriel
    Sharvit, Gal
    Zlotnik, Maya
    Nagler, Arnon
    Shimoni, Avichai
    Avigdor, Abraham
    Canaani, Jonathan
    ANNALS OF HEMATOLOGY, 2022, 101 (02) : 309 - 316
  • [49] Literature review and expert opinion on the treatment of high-risk acute myeloid leukemia in patients who are eligible for intensive chemotherapy
    Palmieri, Raffaele
    Billio, Atto
    Ferrara, Felicetto
    Galimberti, Sara
    Lemoli, Roberto M.
    Todisco, Elisabetta
    Moretti, Federico
    Venditti, Adriano
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [50] Identification of Predictors for Uncomplicated, Low-Risk Febrile Neutropenia (FN) Admissions for Patients with Acute Myeloid Leukemia (AML) Following Intensive Chemotherapy
    Ali, Zahra
    Othus, Megan
    Walter, Roland
    Halpern, Anna
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S193 - S194